Abstract: A curable composition apportioned between at least one Part A and at least one Part B, the Parts sealed within barrier means in manner to prevent contamination thereof, the composition comprising: (i) one or more alkenyl-containing prepolymers having at least one alkenyl moiety per molecule, (ii) one or more SiH-containing prepolymers having at least one SiH unit per molecule, and additionally: (iii) a catalyst for curing by addition of alkenyl-containing prepolymer (i) to SiH-containing prepolymer (ii), wherein the at least one Part A and at least one Part B are provided within or upon at least two respective receptacles or supports and are adapted to be dispensed or released therefrom in cooperative manner facilitating intimate contact and curing thereof, wherein the receptacle(s) or support(s) for at least one of Part A and Part B is thermally stable at elevated temperature of 123 C for a period in excess of 18 hours, methods for preparing the composition, methods for sterilisation thereof, medical and

Abstract: An implantable delivery device and method for utilizing the device to delivery a bioactive agent to a subject in need thereof is described. The device includes a pattern of structures fabricated on a surface of the device to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. The device may be located adjacent tissue such as an endovascular implant or a perivascular implant, and may deliver the bioactive agent without triggering an immune or foreign body response to the bioactive agent.

Abstract: Provided herein are compositions and methods for treating respiratory and pulmonary vascular disease. In particular, provided herein are spray dried simvastatin for delivery to the lung.

Abstract: A method for making a therapeutic agent-eluting temporary medical implant. In various embodiments, the method includes normalizing a quantity of therapeutic agent particles to attain a size distribution of 0.1-100 microns; creating a non-solid blend of a polymer and at least one therapeutic agent including between about 0.1 and about 20.0 weight percent of at least one therapeutic agent to a total weight of the non-solid blend; vat polymerizing the non-solid polymer blend to produce a therapeutic-eluting implant including at least one therapeutic agent homogenously distributed throughout; and cleaning and curing the therapeutic agent-eluting implant to produce a final device that supports physiologic loads when implanted within the patient. In at least one embodiment, the method includes of using a therapeutic agent that includes of one or more antibiotic, antifungal, analgesic, and/or chemotherapeutic.

Abstract: A medical device adapted for contact with a vessel or cavity in the body including a tubular portion is provided. The device has an external surface including an external substance that is at least one of a coating or an impregnation, comprising alexidine in an amount that is both anti thrombogenically effective and anti microbially effective. The device also has an internal surface including an internal substance that is at least one of a coating or an impregnation, comprising alexidine in an amount that is both anti thrombogenically effective and anti microbially effective.

Abstract: A cosmetic or dermocosmetic agent consisting of: galactomannans having molecular weights between 5 and 630 kDa, and crosslinked sulfated galactans having molecular weights between 7 and 3000 kDa. Methods of using the agent, including for skin tensing and rejuvenation.

Abstract: This invention relates according to a solid cosmetic composition for makeup or treatment comprising: —a continuous fatty phase comprising at least one silicone polyamide, at least one non-volatile polar hydrocarbon-based oil and at least one polar wax of which the melting point is less than or equal to 90° C.; and—an aqueous phase dispersed in the continuous fatty phase, said silicone polyamide representing at most 9% by weight with respect to the total weight of said composition, and said wax representing at least 7% by weight with respect to the total weight of said composition.

Abstract: A cosmetic composition includes, in a physiologically acceptable medium: at least water, at least alkylcellulose, at least one first hydrocarbon-based non-volatile oil, chosen from: C10-C26 alcohols, preferably monoalcohols; optionally hydroxylated monoesters, diesters or triesters of a C2-C8 monocarboxylic or polycarboxylic acid and of a C2-C8 alcohol; esters of a C2-C8 polyol and of one or more C2-C8 carboxylic acids. At least one second non-volatile oil chosen from silicone oils and/or fluoro oils or hydrocarbon-based oils other than the said first oil; at least one stabilizer chosen from surfactants and/or hydrophilic gelling agents, preferably chosen from associative polymers, natural polymers and their mixture.

Abstract: Compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at least one pharmaceutically acceptable organic acid, use of said compositions in the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and/or in the prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery and processes for the preparation of said compositions.

Abstract: The present invention relates to foam. In particular, the present invention relates to profiled foams and processes for profiling absorbent foam products. More particularly, the present invention relates to processes for producing a profiled absorbent polyurethane foam product, comprising the steps of foaming, curing, profiling and drying, wherein profiling occurs before drying; and absorbent aliphatic polyurethane foam products having at least one profiled surface.

Abstract: The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C6-C24 fatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a D90 particle size of about 0.5 ?m to about 25 ?m in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25° C.

Abstract: Cosmetic compositions, systems and methods for conferring responsive durable shaping of keratinous fibers employ at least one shape memory polymer that includes a four-armed branched polyethylene glycol (PEG) based polymer that is functionalized with one or more metal-coordination active groups. The shape memory polymer forms a crosslinked network coating on a substrate, for example a substrate selected from keratinous substrates, for example, hair. Hair coated with the shape memory polymer and treated with an oxidizing agent can be shaped, locked into shape, and reprogrammed by modulation of pH. The coated hair retains durable shaping properties through at least one shampoo treatment. The cosmetic compositions, systems and methods provide durable and reprogrammable durable shaping of the keratinous substrate, for example for styling hair.

Abstract: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

Abstract: Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and an additive.

Abstract: Provided is a composition including: an acrylamide compound represented by general formula (1) below; urethane (meth)acrylate having a SI value of 3 or less in a skin sensitization test; and a polymerization initiator having a molecular weight of 800 or greater, where in general formula (1), R1 represents an alkyl group containing 1 through 6 carbon atoms, X represents an alkylene group containing 1 through 6 carbon atoms, and Y represents any one selected from the group consisting of general formula (2) below and general formula (3) below, where in general formula (2), R2 represents an alkyl group containing 1 through 10 carbon atoms, and * represents a binding site with X above, where in general formula (3), R2 represents an alkyl group containing 1 through 10 carbon atoms, and * represents a binding site with X above.

Abstract: The present invention provides a patch comprising a backing layer and an adhesive agent layer, wherein the adhesive agent layer is non-aqueous, the adhesive agent layer contains nonylic acid vanillylamide and aluminum hydroxide, a content of nonylic acid vanillylamide in the adhesive agent layer is 0.01 to 0.025% by mass based on a total mass of the adhesive agent layer, a content of aluminum hydroxide in the adhesive agent layer is 0.55 to 1.5% by mass based on the total mass of the adhesive agent layer, and a mass ratio of the content of nonylic acid vanillylamide to the content of aluminum hydroxide ((content of nonylic acid vanillylamide):(content of aluminum hydroxide)) in the adhesive agent layer is 1:27 to 1:150.

Abstract: The present invention relates to an acetaminophen injectable aqueous solution for use in the treatment or in the prevention of pain by spinal administration, wherein said acetaminophen injectable solution is supersaturated. In certain embodiments, the acetaminophen injectable aqueous solution is administered simultaneously, separately or sequentially with a local anaesthetic by spinal administration.

Abstract: Disclosed are soft gelatin capsules comprising a gelatin shell, a plasticiser, water, and optionally a calcium salt and a filling containing a dispersed or solubilised medicament comprising gelatin with gelling power, hydrolysed gelatin, glycerol, water, pectin and gellan gum. The formulations according to the invention allow gradual release of the active ingredient, regardless of pH.

Abstract: The present invention provides compositions and methods for the dietary management of nephrolithiasis and hypocitraturia through the oral administration of multiple alkali salts including sodium bicarbonate, potassium citrate and/or magnesium citrate. Also provided are kits including compositions for the dietary management of nephrolithiasis and hypocitraturia.

Abstract: Disclosed are a ceria nanocomposite for biomedical treatment, including a ceria nanoparticle; and a pharmaceutical composition. The disclosed ceria nanocomposite for biomedical treatment includes a ceria nanoparticle and a surface modification layer arranged on the surface of the ceria nanoparticle, wherein the surface modification layer includes a polyethylene glycol residue, and in the ceria nanoparticle, the content of Ce3+ is greater than the content of Ce4+.